Literature DB >> 16720337

Mechanisms controlling CDK9 activity.

Renee M Marshall1, Xavier Grana.   

Abstract

This review primarily focuses on the mechanisms that modulate CDK9 activity and its recruitment to cellular genes, where it phosphorylates the C-terminal domain of RNA polymerase II (RNAPII) as well as negative elongation factors. CDK9 associates with each of four cyclins (T1, T2a, T2b and K), forming distinct positive transcription elongation factors (P-TEFb). Research done during the past decade has demonstrated a role for P-TEFb in stimulating elongation of otherwise paused RNAPII transcripts. Recent work suggests that P-TEFb also positively modulates other steps during transcription. In addition, "abnormal" CDK9 function is associated with certain diseases. Specifically, the activity of the cyclin T1/CDK9 complex is essential for HIV-1 replication and CDK9 upregulation is associated with cardiac hypertrophy. Thus, the role of CDK9 in these processes, and the possibility of therapeutically targeting CDK9, will also be briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720337     DOI: 10.2741/1994

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  18 in total

Review 1.  RNA polymerase II elongation control.

Authors:  Qiang Zhou; Tiandao Li; David H Price
Journal:  Annu Rev Biochem       Date:  2012-03-09       Impact factor: 23.643

2.  Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.

Authors:  Christopher Abdullah; Xiaolei Wang; Dorothea Becker
Journal:  Cell Cycle       Date:  2011-03-15       Impact factor: 4.534

3.  Cyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review).

Authors:  Yeming Han; Yang Zhan; Guihua Hou; Li Li
Journal:  Biomed Rep       Date:  2014-07-31

Review 4.  Epigenomics of T cell activation, differentiation, and memory.

Authors:  Suresh Cuddapah; Artem Barski; Keji Zhao
Journal:  Curr Opin Immunol       Date:  2010-03-11       Impact factor: 7.486

5.  Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Authors:  Koen Bartholomeeusen; Koh Fujinaga; Yanhui Xiang; B Matija Peterlin
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

6.  Selective control of gene expression by CDK9 in human cells.

Authors:  Judit Garriga; Hongbo Xie; Zoran Obradovic; Xavier Graña
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

7.  Cell cycle-related kinase in carcinogenesis.

Authors:  Ye Tian; Han Wan; Guang Tan
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

8.  The Smad3/Smad4/CDK9 complex promotes renal fibrosis in mice with unilateral ureteral obstruction.

Authors:  Xinli Qu; Mengjie Jiang; Yu Bo Yang Sun; Xiaoyun Jiang; Ping Fu; Yi Ren; Die Wang; Lie Dai; Georgina Caruana; John F Bertram; David J Nikolic-Paterson; Jinhua Li
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

9.  Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.

Authors:  Dominic Salerno; Muneer G Hasham; Renée Marshall; Judit Garriga; Alexander Y Tsygankov; Xavier Graña
Journal:  Gene       Date:  2007-09-19       Impact factor: 3.688

10.  The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes.

Authors:  Susan Nozell; Travis Laver; Dorothy Moseley; Lisa Nowoslawski; Marijke De Vos; George P Atkinson; Keith Harrison; L Burton Nabors; Etty N Benveniste
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.